Attorney Docket No. 5079P2C1

RECEIVED
CENTRAL FAX CENTER
APR 07 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of Yamin Wang, et al.

Serial No.: 10/684,299 Group Art Unit: 1625

Filed: October 10, 2003 Examiner: Bernard I. Dentz

For: 1,6-Naphthyridine Derivatives and Their Use to Treat Diabetes and Related Disorders

CERTIFICATION OF MAILING UNDER 37 C.F.R. 1.8(a)

I hereby certify that this correspondence and any papers referred to as attached are being facsimile transmitted to the U.S. Patent and Trademark Office at (703) 872-9306.

Date: April 7, 2005 Susan M. Pellegrino
Susan M. Pellegrino

REPLY AND AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In reply to the Office Action mailed February 4, 2005 (Paper No. 20050203), Applicants respectfully request reconsideration and reexamination of the present application in view of the following remarks.

REMARKS

Claims 41-44 are pending in this application.

Double Patenting

The Examiner has rejected claims 41-44 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 26-28 of U.S. Patent No. 6,677,352 (Paper No. 20050203, page 2).

To expedite prosecution of the pending application, Applicants have elected to file a terminal disclaimer.

It is submitted that Applicants have overcome the claim rejection, and thus, claims 41-44 are allowable.